You are here

hemophilia B

First Gene Therapy for Hemophilia B, CSL's HEMGENIX®, Approved by the European Commission

First Gene Therapy for Hemophilia B, CSL's HEMGENIX®, Approved by the European Commission

BioSpace

Flag link:

Pfizer says hemophilia B gene therapy controlled bleeding in key study

Pfizer says hemophilia B gene therapy controlled bleeding in key study

BioPharma Dive

fidanacogene elaparvovec

Flag link:

Despite Eye-Popping $3.5 Million Price Tag For Gene Therapy Hemgenix, Budget Impact For Most Payers Will Be Relatively Small

Despite Eye-Popping $3.5 Million Price Tag For Gene Therapy Hemgenix, Budget Impact For Most Payers Will Be Relatively Small

Forbes

Flag link:

Freeline's One Dose Gene Therapy could Transform Hemophilia B Treatment

Freeline's One Dose Gene Therapy could Transform Hemophilia B Treatment

BioSpace

clinical trials

Freeline Therapeutics

Flag link:

CSL-UniQure Hemophilia B Gene Therapy Scores Priority Review

CSL-UniQure Hemophilia B Gene Therapy Scores Priority Review

BioSpace

priority review

etranacogene dezaparvovec

Flag link:

Fresh data show UniQure's hemophilia gene therapy appears to hold up

Fresh data show UniQure's hemophilia gene therapy appears to hold up

BioPharma Dive

Flag link:

Uniqure's Hemophilia B Gene Therapy Unlikely To Be Cause Of Liver Cancer Reported In One Patient

Uniqure's Hemophilia B Gene Therapy Unlikely To Be Cause Of Liver Cancer Reported In One Patient

Benzinga

etranacogene dezaparvovec

clinical trials

Flag link:

Gene therapy for hemophilia: So close, yet so far away

Gene therapy for hemophilia: So close, yet so far away

BioPharma Dive

Flag link:

UniQure/CSL hit by FDA clinical hold for hem B gene therapy program after liver cancer find

UniQure/CSL hit by FDA clinical hold for hem B gene therapy program after liver cancer find

Fierce Biotech

clinical trials

etranacogene dezaparvovec

Flag link:

UniQure out-licenses hemophilia B gene therapy in deal valued up to ~$2.1B

UniQure out-licenses hemophilia B gene therapy in deal valued up to ~$2.1B

Seeking Alpha

etranacogene dezaparvovec

Flag link:

Regeneron to expand development deal with Intellia Therapeutics

Regeneron to expand development deal with Intellia Therapeutics

Marketwatch

Intellia Therapeutics

drug development

Flag link:

Value-based pricing for gene therapy? Maybe not ready for hemophilia

Value-based pricing for gene therapy? Maybe not ready for hemophilia

Biopharma Dive

valoctocogene roxaparvovec

Flag link:

UniQure stays a step ahead in hemophilia B

UniQure stays a step ahead in hemophilia B

Biopharma Dive

clinical trials

Flag link:

This Gene Therapy Stock Could Soon Hit The Auction Block — Here's Why

This Gene Therapy Stock Could Soon Hit The Auction Block — Here's Why

Investors Business Daily

Spark Therapeutics

Flag link:

Uniqure turns the screw on Spark and Pfizer

Uniqure turns the screw on Spark and Pfizer

EP Vantage

Spark Therapeutics

Flag link:

UniQure’s hemophilia B gene therapy achieves 31% FIX activity

UniQure’s hemophilia B gene therapy achieves 31% FIX activity

Fierce Biotech

Flag link:

Pfizer's Hemophilia B Gene Therapy Candidate Enters Phase III

Pfizer's Hemophilia B Gene Therapy Candidate Enters Phase III

Zacks.com

fidanacogene elaparvovec

Flag link:

Spark, Pfizer pass another milestone with impressive results treating hemophilia B

Spark, Pfizer pass another milestone with impressive results treating hemophilia B

Endpoints

Spark Therapeutics

Flag link:

Spark's Hemophilia Gene Therapy Remains Effective Despite Immune Reactions

Spark's Hemophilia Gene Therapy Remains Effective Despite Immune Reactions

TheStreet.com

Spark Therapeutics

Flag link:

Shire cans Baxalta hemophilia B gene therapy, thinning field for uniQure, Spark

Shire cans Baxalta hemophilia B gene therapy, thinning field for uniQure, Spark

Fierce Biotech

Spark Therapeutics

Flag link:

Pages